Ascendis Pharma (ASND) Revenue & Revenue Breakdown
Ascendis Pharma Revenue Highlights
Latest Revenue (Y)
$266.72M
Latest Revenue (Q)
$95.89M
Main Geography (Y)
North America
Ascendis Pharma Revenue by Period
Ascendis Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $266.72M | 421.20% |
| 2022-12-31 | $51.17M | 557.93% |
| 2021-12-31 | $7.78M | 11.87% |
| 2020-12-31 | $6.95M | -48.01% |
| 2019-12-31 | $13.38M | 26.41% |
| 2018-12-31 | $10.58M | 591.57% |
| 2017-12-31 | $1.53M | -66.78% |
| 2016-12-31 | $4.61M | -43.26% |
| 2015-12-31 | $8.12M | -41.94% |
| 2014-12-31 | $13.98M | -31.48% |
| 2013-12-31 | $20.41M | 30.96% |
| 2012-12-31 | $15.58M | - |
Ascendis Pharma generated $266.72M in revenue during NA 2023, up 421.20% compared to the previous quarter, and up 2520.73% compared to the same period a year ago.
Ascendis Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $95.89M | -30.36% |
| 2023-12-31 | $137.70M | 186.68% |
| 2023-09-30 | $48.03M | 1.35% |
| 2023-06-30 | $47.39M | 41.10% |
| 2023-03-31 | $33.59M | 46.70% |
| 2022-12-31 | $22.90M | 49.74% |
| 2022-09-30 | $15.29M | 148.21% |
| 2022-06-30 | $6.16M | -9.78% |
| 2022-03-31 | $6.83M | 39.43% |
| 2021-12-31 | $4.90M | 339.98% |
| 2021-09-30 | $1.11M | 8.90% |
| 2021-06-30 | $1.02M | 37.00% |
| 2021-03-31 | $746.00K | 39.44% |
| 2020-12-31 | $535.00K | -80.59% |
| 2020-09-30 | $2.76M | 91.99% |
| 2020-06-30 | $1.44M | -35.46% |
| 2020-03-31 | $2.23M | -11.25% |
| 2019-12-31 | $2.51M | 11.77% |
| 2019-09-30 | $2.24M | -30.15% |
| 2019-06-30 | $3.21M | -40.69% |
| 2019-03-31 | $5.41M | -48.51% |
| 2018-12-31 | $10.52M | 52475.00% |
| 2018-09-30 | $20.00K | 11.11% |
| 2018-06-30 | $18.00K | -35.71% |
| 2018-03-31 | $28.00K | -90.00% |
| 2017-12-31 | $280.00K | -35.48% |
| 2017-09-30 | $434.00K | -2.25% |
| 2017-06-30 | $444.00K | 19.35% |
| 2017-03-31 | $372.00K | -64.33% |
| 2016-12-31 | $1.04M | -10.78% |
| 2016-09-30 | $1.17M | 2.90% |
| 2016-06-30 | $1.14M | -9.70% |
| 2016-03-31 | $1.26M | -36.37% |
| 2015-12-31 | $1.98M | -6.61% |
| 2015-09-30 | $2.12M | 8.96% |
| 2015-06-30 | $1.94M | -6.63% |
| 2015-03-31 | $2.08M | -26.36% |
| 2014-12-31 | $2.83M | -13.05% |
| 2014-09-30 | $3.25M | -16.94% |
| 2014-06-30 | $3.91M | -2.03% |
| 2014-03-31 | $3.99M | -28.15% |
| 2013-12-31 | $5.56M | - |
Ascendis Pharma generated $95.89M in revenue during Q1 2024, up -30.36% compared to the previous quarter, and up 418.82% compared to the same period a year ago.
Ascendis Pharma Revenue Breakdown
Ascendis Pharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| CHINA | $6.47M | $922.00K | $4.27M | $10.72M | - |
| North America | $44.16M | $6.86M | $2.68M | $2.65M | - |
| Europe | $552.00K | - | - | - | - |
| Country of domicile | - | - | - | - | - |
Latest
Ascendis Pharma's latest annual revenue breakdown by geography, as of Dec 22: North America (86.29%), CHINA (12.64%), and Europe (1.08%).
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 |
|---|---|---|---|---|---|---|---|---|---|
| North America | $33.07M | $19.73M | $-12.89M | $5.08M | $6.46M | $4.78M | $702.00K | $688.00K | $722.00K |
| CHINA | $519.00K | $3.04M | $2.25M | $942.00K | $237.00K | $117.00K | $411.00K | $334.00K | $-187.00K |
| Europe | - | $126.00K | $151.00K | $140.00K | $135.00K | - | - | - | - |
Latest
Ascendis Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: North America (98.45%), and CHINA (1.55%).
Ascendis Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BGNE | BeiGene | $2.46B | $929.17M |
| UTHR | United Therapeutics | $2.33B | $748.90M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| ACLX | Arcellx | $110.32M | $26.03M |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| PLRX | Pliant Therapeutics | $1.58M | - |
| NUVL | Nuvalent | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| REPL | Replimune Group | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| VTYX | Ventyx Biosciences | - | - |
| ETNB | 89bio | - | - |
| AKRO | Akero Therapeutics | - | - |